Abstract：
:Testosterone depletion is the keystone for therapy of patients metastic prostatic carcinoma. Our objective was to investigate Leydig cell function and testosterone levels after withdrawal of long-term endocrine treatment in patients with prostatic carcinoma. Thirteen patients with prostatic carcinoma, previously treated with oestrogens for at least 4 y, were stimulated with 5000 IU human chorionic gonadotrophin (hCG). The stimulation was performed 3-6 y after cessation of the oestrogen therapy. Serum concentrations of testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) were measured before and 24 and 48 h after hCG stimulation. Before hCG stimulation all patients had low serum testosterone concentrations (mean 2.0+/-0.2 nmol/l) and 24 and 48 h after hCG stimulation the values had not significantly increased (mean 2.4+/-0.2 and 2.5+/-1.1 nmol/l, respectively). LH and FSH were within or above the normal range before but after hCG stimulation the values significantly increased. In conclusion, the study shows that the Leydig cells were unable to respond to hCG stimulation more than 3 y after cessation of oestrogen therapy. The Leydig cell function seems to be irreversibly impaired by long-term oestrogen treatment.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Tomic R,Ljungberg Bdoi
10.1038/sj.pcan.4500310subject
Has Abstractpub_date
1999-07-01 00:00:00pages
211-214issue
4eissn
1365-7852issn
1476-5608pii
4500310journal_volume
2pub_type
杂志文章abstract：:The purpose of the present study was to perform a BPH risk factor analysis in men, relating the prostate gland volume to components of the metabolic syndrome and to identify clues to the etiology of BPH. Our material comprised a consecutive series of 158 patients with lower urinary tract symptoms with or without manif...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500221
更新日期：1998-03-01 00:00:00
abstract：BACKGROUND:Utilization of active surveillance (AS) for prostate cancer is increasing. Optimal selection criteria for this approach are undefined and questions remain on how best to expand inclusion beyond typical men with very low- or low-risk disease. We sought to review the current experience with AS for men with int...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,meta分析,评审
doi：10.1038/pcan.2016.51
更新日期：2017-03-01 00:00:00
abstract：INTRODUCTION:Multidisciplinary team (MDT) meetings use precise prognostic factors to select treatment options for patients with prostate cancer. Comorbidity is judged subjectively. Recent publications favour the Charlson comorbidity score (CS) for the use in the management of prostate cancer. We assess the feasibility ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500889
更新日期：2006-01-01 00:00:00
abstract：:Dose-escalated conformal radiotherapy is increasingly being used to radically treat prostate cancer with encouraging results and minimal long-term toxicity, yet little is known regarding the response of normal or malignant prostate cells to ionizing radiation (IR). To clarify the basis for cell killing during prostate...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500628
更新日期：2003-01-01 00:00:00
abstract：:With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4501015
更新日期：2008-01-01 00:00:00
abstract：:This study investigated the hypothesis that, in benign prostatic hyperplasia (BPH), upregulated oestrogen receptors (ER) and the action of androgens differentially regulate expression of stromal growth factors. Eight human prostatic stromal cell strains were subjected to a procedure to upregulate their ER by exposing ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500692
更新日期：2004-01-01 00:00:00
abstract：:This literature review discusses the theoretical background of 5alpha-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2008.56
更新日期：2009-01-01 00:00:00
abstract：:We present a critical review of the recent literature and discuss the development and prospective view of the evaluations of transrectal ultrasound with regard to prostate malignancy. We illustrate this with personal experiences. Material and Methods: Based on a critical evaluation of clinical data we address the appa...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500326
更新日期：1999-12-01 00:00:00
abstract：INTRODUCTION:Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS:Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason <...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-020-00315-y
更新日期：2021-01-28 00:00:00
abstract：BACKGROUND:Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/s41391-018-0060-y
更新日期：2018-11-01 00:00:00
abstract：BACKGROUND:Intermittent androgen deprivation (IAD) for prostate cancer was studied with the objective of reducing the side effects of treatment and potentially delaying the development of hormone resistance. There also appears to be a quality of life benefit during off-treatment intervals owing to the recovery of serum...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1038/pcan.2012.12
更新日期：2012-09-01 00:00:00
abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2011.28
更新日期：2011-12-01 00:00:00
abstract：:Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500609
更新日期：2003-01-01 00:00:00
abstract：BACKGROUND:Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.45
更新日期：2016-12-01 00:00:00
abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2014.28
更新日期：2014-12-01 00:00:00
abstract：:In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as wel...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500302
更新日期：1999-05-01 00:00:00
abstract：:Epidemiological studies have suggested an association between low selenium levels and the development of prostate cancer. Human cellular glutathione peroxidase I (hGPX1) is a selenium-dependent enzyme that protects against oxidative damage and its peroxidase activity is a plausible mechanism for cancer prevention by s...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500569
更新日期：2002-01-01 00:00:00
abstract：BACKGROUND:Intermittent androgen suppression (IAS) is an increasingly popular treatment option for castrate-sensitive prostate cancer. On the basis of previous data with anti-angiogenic strategies, we hypothesized that pan-inhibition of the vascular endothelial growth factor receptor using pazopanib during the IAS off ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.1038/pcan.2011.49
更新日期：2012-03-01 00:00:00
abstract：BACKGROUND:Several treatment options for clinically localized prostate cancer currently exist under the established guidelines. We aim to assess nationally representative trends in treatment over time and determine potential geographic variation using two large national claims registries. METHODS:Men with prostate can...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2015.3
更新日期：2015-06-01 00:00:00
abstract：:The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR)....
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,多中心研究
doi：10.1038/sj.pcan.4500882
更新日期：2006-01-01 00:00:00
abstract：BACKGROUND:Treatment of high-risk prostate cancer has evolved considerably over the past two decades, yet patients with very-high-risk features may still experience poor outcome despite aggressive therapy. We review the contemporary literature focusing on current definitions, role of modern imaging and treatment altern...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章,评审
doi：10.1038/pcan.2016.40
更新日期：2016-12-01 00:00:00
abstract：BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2013.33
更新日期：2013-12-01 00:00:00
abstract：OBJECTIVE:To determine whether the duration of the off-treatment interval in patients being treated with intermittent androgen deprivation therapy can be predicted by the length of the CAG trinucleotide repeat polymorphism in the androgen receptor. METHODS:This is a companion study to a prospective randomized trial, N...
journal_title：Prostate cancer and prostatic diseases
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.pcan.4500792
更新日期：2005-01-01 00:00:00
abstract：:Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500796
更新日期：2005-01-01 00:00:00
abstract：:In a prospective randomized study, we compare standard prostate biopsy to extensive biopsy utilizing intravenous conscious sedation (IVCS). Initial biopsy patients (n=197) were randomized to either standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1) or extensive biopsy (24 biopsies) using IVCS. ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.1038/sj.pcan.4500713
更新日期：2004-01-01 00:00:00
abstract：BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.67
更新日期：2017-06-01 00:00:00
abstract：:The purpose of this paper is to examine effects of finasteride 5 mg across different age groups in an ethnically diverse population of men with symptomatic benign prostatic hyperplasia (BPH) seen in community urology and primary care practices. Data were combined from two previous placebo-controlled randomised trials ...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500202
更新日期：1997-09-01 00:00:00
abstract：:The present study seeks to establish a relationship between the quality of a surgical procedure and the subsequent hospital costs for that procedure by investigating the influence of both patient and peri-operative factors on the hospital costs of radical prostatectomy. All men who underwent radical prostatectomy at o...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4500529
更新日期：2001-01-01 00:00:00
abstract：BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/pcan.2016.38
更新日期：2016-12-01 00:00:00
abstract：:The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...
journal_title：Prostate cancer and prostatic diseases
pub_type： 杂志文章
doi：10.1038/sj.pcan.4501001
更新日期：2008-01-01 00:00:00
